Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nyse  >  Johnson & Johnson    JNJ

JOHNSON & JOHNSON

(JNJ)
  Report  
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsOfficial PublicationsSector newsAnalyst Recommendations

Johnson & Johnson : J&J's Janssen Gets EC OK for Expanded Use of Imbruvica

share with twitter share with LinkedIn share with facebook
share via e-mail
0
08/13/2019 | 07:39am EDT

By Colin Kellaher

Johnson & Johnson's (JNJ) Janssen Pharmaceutical Cos. unit on Tuesday said the European Commission approved the use of Imbruvica in two additional indications.

Janssen said Imbruvica is now approved in combination with obinutuzumab in adults with previously untreated chronic lymphocytic leukemia, and in combination with rituximab for adults with Waldenstrom's macroglobulinemia, a rare and incurable type of non-Hodgkin's lymphoma.

The European Medicines Agency's Committee for Medicinal Products for Human Use in June recommended EC approval of the expanded use of Imbruvica.

Write to Colin Kellaher at colin.kellaher@wsj.com

share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on JOHNSON & JOHNSON
08/21JOHNSON & JOHNSON : Trump signs student debt forgiveness for disabled veterans
AQ
08/21JOHNSON & JOHNSON : Oklahoma judge expected to rule Monday in opioid case
AQ
08/19JOHNSON & JOHNSON : Congo to use second vaccine to fight Ebola
AQ
08/16JOHNSON & JOHNSON INVESTIGATION UPDA : Kahn Swick & Foti, LLC Continues to Inves..
BU
08/16JOHNSON & JOHNSON : Ebola Crisis-The Vaccines Debate
AQ
08/15JOHNSON & JOHNSON : Janssen Announces European Commission Approval of Imbruvica ..
AQ
08/13JOHNSON & JOHNSON : J&J's Janssen Gets EC OK for Expanded Use of Imbruvica
DJ
08/12JOHNSON & JOHNSON : Thinking about trading options or stock in AbbVie, Bristol-M..
PR
08/12JOHNSON & JOHNSON : Janssen Announces U.S. FDA Accelerated Approval for SIRTURO ..
AQ
08/09JOHNSON & JOHNSON : Janssen Announces U.S. FDA Accelerated Approval for SIRTUROÒ..
PU
More news
Financials (USD)
Sales 2019 81 594 M
EBIT 2019 25 389 M
Net income 2019 18 319 M
Debt 2019 5 892 M
Yield 2019 2,86%
P/E ratio 2019 19,6x
P/E ratio 2020 17,3x
EV / Sales2019 4,33x
EV / Sales2020 4,07x
Capitalization 347 B
Chart JOHNSON & JOHNSON
Duration : Period :
Johnson & Johnson Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends JOHNSON & JOHNSON
Short TermMid-TermLong Term
TrendsBearishBearishNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 21
Average target price 148,50  $
Last Close Price 131,53  $
Spread / Highest target 28,5%
Spread / Average Target 12,9%
Spread / Lowest Target -5,72%
EPS Revisions
Managers
NameTitle
Alex Gorsky Chairman & Chief Executive Officer
Joseph J. Wolk Chief Financial Officer & Executive Vice President
Charles O. Prince Independent Director
William David Perez Independent Director
Anne M. Mulcahy Lead Independent Director
Sector and Competitors
1st jan.Capitalization (M$)
JOHNSON & JOHNSON1.20%347 129
ROCHE HOLDING LTD.12.16%238 668
MERCK AND COMPANY13.74%222 522
NOVARTIS17.97%206 833
PFIZER-20.71%192 868
NOVO NORDISK AS15.68%123 385